



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

IOLCP/CGC/2015
13 August 2015

The General Manager
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051

The General Manager
Bombay Stock Exchange Limited.
Phiroze Jeejeebhoy Towers,
Dalal Street
Mumbai

Sub: Un-audited Financial Results

Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith copy of the Un-audited Financial Results and Segment Report for the quarter ended 30 June 2015 alongwith the Limited Review Certificate of the Statutory Auditor.

This is for your information and record please.

Thanking you

Yours faithfully,
for IOL Chemicals and Pharmaceuticals Limited


[Krishan Singla]
Vice President & Company Secretary

Encl : 1. Un-audited Financial Results & Segment Report
2. Limited review certificate

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Ph.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Ph.) India
Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Ph.) India
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292




IOL CHEMICALS AND PHARMACEUTICALS LIMITED

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2015

Rs. in Lacs

Sr. No.	Particulars	Quarter Ended			Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
		30.06.2015	31.03.2015	30.06.2014	31.03.2015
1	Income from Operations				
a	Net Sales / Income from operations (net of excise duty)	13694.42	7482.74	12086.25	38472.53
b	Other Operating Income	28.47	44.58	32.07	129.86
	Total income from Operations (net)	13722.89	7527.32	12118.32	38602.39
2	Expenses				
a	Cost of materials consumed	10499.87	7150.79	8146.38	30085.22
b	Purchase of stock-in-trade	0.00	0.00	0.00	0.00
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3.14)	(1125.22)	(706.25)	(2162.43)
d	Employee benefits expense	787.90	574.04	649.37	2471.85
e	Depreciation and amortisation expense	737.11	726.79	781.52	2891.05
f	Other expenditure	2223.79	1820.31	1542.24	6951.76
	Total Expenses	14245.53	9146.71	10413.26	40237.45
3	Profit from Operations before Other Income, finance cost and Exceptional Items (1-2)	(522.64)	(1619.39)	1705.06	(1635.06)
4	Other Income	0.45	0.45	0.45	1.80
5	Profit from ordinary activities before finance cost and exceptional items (3+4)	(522.19)	(1618.94)	1705.51	(1633.26)
6	Finance costs	1453.74	1474.75	1514.67	5910.54
7	Profit from ordinary activities after finance costs but before exceptional items (5-6)	(1975.93)	(3093.69)	190.84	(7543.80)
8	Exceptional Items	0.00	0.00	0.00	0.00
9	Profit (+) / Loss (-) from ordinary activities before tax (7+8)	(1975.93)	(3093.69)	190.84	(7543.80)
10	Tax Expense	(181.75)	(288.14)	65.72	(878.73)
11	Net Profit (+)/Loss (-) from ordinary activities after tax (9-10)	(1794.18)	(2805.55)	125.12	(6665.07)
12	Extraordinary Item (net of tax expense)				
13	Net Profit (+)/Loss (-) for the period (11-12)	(1794.18)	(2805.55)	125.12	(6665.07)
14	Paid-up equity share capital (Face value Rs.10/- Per Share)	4995.55	4765.55	3816.16	4765.55
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				15355.96
16	Earning per share (before and after extraordinary item (Face value of Rs. 10/- each)				
	Basic	(3.72)	(6.38)	0.42	(16.72)
	Diluted	(3.44)	(6.97)	0.42	(16.63)
	Cash	(2.57)	(5.55)	3.13	(11.67)



Head Office : 85, Industrial Area 'A', Ludhiana, 141 003 (Pb.) India CIN - L21116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Pb.) India
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Pb.) India
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

PART-II SELECT INFORMATION FOR THE PERIOD ENDED 30 JUNE 2015

Sr. No.	Particulars	Quarter Ended			Year Ended
		(Unaudited) 30.06.2015	(Unaudited) 31.03.2015	(Unaudited) 30.06.2014	(Audited) 31.03.2015
A	Particulars of Shareholding				
1	Public Shareholding				
	-- No of Shares	27518536	25218536	15762325	25218536
	-Percentage of Shareholding	55.09	52.92	41.30	52.92
2	Promoters and promoter group Shareholding				
	a) Pledged/Encumbered				
	- Number of shares		-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)		-	-	-
	- Percentage of shares (as a % of the total share capital of the company)		-	-	-
	b) Non-encumbered				
	- Number of shares	22436966	22436966	22399266	22436966
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	44.91	47.08	58.70	47.08

B	Particulars	3 months ended 30 June 2015
	Investor Complaints	
1	Pending at the beginning of the quarter	NIL
2	Received during the quarter	NIL
3	Disposed of during the quarter	NIL
4	Remaining unresolved at the end of the quarter	NIL



Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Ph.) India CIN - L24116PB1986PLC007030
 Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
 Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Ph.) India
 Works : Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Ph.) India
 Ph. : +91-1679 -285285-86, Fax : +91-1679-285292



IOL CHEMICALS AND PHARMACEUTICALS LIMITED

Segment wise Revenue, Results and Capital Employed, under clause 41 of the Listing Agreement

Rs. in Lacs

Particulars	Quarter Ended			Year Ended
	Unaudited	Unaudited	Unaudited	Audited
	30.06.2015	31.03.2015	30.06.2014	31.03.2015
1. Segment Revenue				
(Net sale/income)				
- Chemicals	8369.25	4323.78	7901.72	24648.58
- Drugs	7552.68	5144.34	6051.37	21092.56
- Unallocated	41.16	47.65	52.63	256.89
Total	15963.09	9515.77	14005.72	45998.03
Less : Inter segment revenue	2240.20	1988.45	1887.40	7395.64
Net sales/income from operations	13722.89	7527.32	12118.32	38602.39
2. Segment Results				
Profit(+)/(loss)(-) before tax and interest from each segment)				
- Chemicals	(1712.72)	(1967.12)	(113.25)	(5045.31)
- Drugs	1184.51	314.38	1780.03	3182.53
Total	(528.21)	(1652.74)	1666.78	(1862.78)
Less: Interest	1453.74	1474.75	1514.67	5910.54
Less: Other un-allocable expenditure net of unallocable income	(6.02)	(33.80)	(38.73)	(229.52)
Total Profit(+)/(loss) (-) before tax & Extraordinary items	(1975.93)	(3093.69)	190.84	(7543.80)
3. Capital Employed				
(Segment assets - Segment Liabilities)				
- Chemicals	5082.23	8750.54	10381.13	8750.54
- Drugs	13151.68	11040.72	11251.92	11040.72
- Unallocated	1174.92	967.07	1098.17	967.07
Total	19408.83	20758.33	22731.22	20758.33

NOTES:

- The above results have been reviewed by the Audit & Risk Management Committee and were considered and approved by the Board of the Directors at their meeting held on 13 August 2015
- The successful completion of inspection by USFDA of Ibuprofen manufacturing facilities has leveled the Company with its peers and resulted in improving perception of the Company. The Company continues to enjoy the edge over other Ibuprofen manufacturers in the world, having in-house backward integrated manufacturing facilities.
- During the quarter ended 30 June 2015, the Company has allotted 23,00,000 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the non promoters, on exercise of the option attached with warrants allotted on 04 July 2014. The paid up capital of the company increased from 4,76,55,502 equity shares of Rs10/- each to 4,99,55,502 equity shares of Rs 10/- each.
- During the current quarter, Company has allotted 10,00,000 equity shares of Rs 10/- each at a premium of Rs 18/- per share to the non promoters, on exercise of the option attached with warrants allotted on 04 July 2014 resulting increase in paid up capital to 5,09,55,502 equity shares of Rs 10 each.
- Previous period's figures have been regrouped/ reclassified wherever necessary.
- Limited review of the above unaudited financial results of the Company in term of Clause 41 of the Listing Agreement has been carried out by the Statutory Auditors of the Company

By order of the Board
For IOL Chemicals and Pharmaceuticals Limited

Place: Ludhiana
Date: 13 August 2015



Sd/-
Vijay Kumar Garg
Joint Managing Director
DIN: 06510248

Head Office : 85, Industrial Area 'A', Ludhiana. 141 003 (Ph.) India CIN - L24116PB1986PLC007030
Ph. : +91-161-2225531-35 Fax : +91-161-2226929, 2608784 email : contact@iolcp.com Website : iolcp.com
Regd. Office : Trident Complex, Raikot Road, Barnala - 148 101 (Ph.) India
Works: Trident Complex, Mansa Road, Vill Fatehgarh Channa, Barnala-148101. (Ph.) India
Ph. : +91-1679 -285285-86, Fax : +91-1679-285292

REVIEW REPORT

To
The Board of Directors,
IOL Chemicals and Pharmaceuticals Limited
Ludhiana

Introduction

We have reviewed the accompanying statement of unaudited financial results of IOL Chemicals and Pharmaceuticals Limited (the Company) for the quarter and three months ended 30th June, 2015 except for the disclosure regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on this statement based on our review.

Scope of Review

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we could become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

CERTIFIED TO BE TRUE COPY

Place: Ludhiana

Date: 13th August, 2015

For IOL Chemicals and Pharmaceuticals Limited



For S.C. Vasudeva & Co.
Chartered Accountants
FRN- 000235N

(Sanjay Mohan)
Partner
M. No. 086066

Krishan Singla

Vice President & Company Secretary